Finance

Beta
Lists
ABBV:NYSE
AbbVie Common Stock
$230.01
+6.25%
(+13.52) 1D
$229.99
-0.01% (-0.023)
After hours
Closed: Jun 22, 4:05:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV...
Open
$221.94
High
$232.32
Low
$221.94
Mkt. cap
406.38B
Avg. vol.
5.54M
Volume
0.00
Dividend
3.01%
Quarterly dividend
$1.73
Ex-dividend date
Jul 15, 2026
P/E ratio
113.51
52-wk high
$244.81
52-wk low
$181.73
EPS
$2.03
Beta
0.32
Shares outstanding
1.77B
No. of employees
57K
Open
$221.94
High
$232.32
Low
$221.94
Mkt. cap
406.38B
Avg. vol.
5.54M
Volume
0.00
Dividend
3.01%
Quarterly dividend
$1.73
Ex-dividend date
Jul 15, 2026
P/E ratio
113.51
52-wk high
$244.81
52-wk low
$181.73
EPS
$2.03
Beta
0.32
Shares outstanding
1.77B
No. of employees
57K
News stories
From sources across the web
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Analyst Ratings
Based on 22 analysts giving stock ratings to ABBV in the past 3 months
Strong Buy
Buy
18
Hold
4
Sell
0
12 month forecast
Based on 22 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current $230.01
$298.00 (+29.56%)
Average
$259.24 (+12.71%)
Lowest
$230.00 (-0.00%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Steve Scala
TD Cowen
Buy
Maintained
$280.00
+21.7%
06/22/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
06/22/2026
Geoff Meacham
Citi
Buy
Maintained
$230.00
-0%
06/21/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$260.00
+13%
06/21/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$258.00
+12.2%
06/19/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/19/2026
Michael Yee
UBS
Hold
Maintained
$230.00
-0%
06/19/2026
Emily Field
Barclays
Buy
Maintained
$275.00
+19.6%
06/12/2026
Courtney Breen
Bernstein
Hold
Maintained
-
-
06/09/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
06/03/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$298.00
+29.6%
06/02/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$278.00
+20.9%
05/31/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
$235.00
+2.2%
05/15/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
$250.00
+8.7%
05/13/2026
Luisa Hector
Berenberg Bank
Buy
Maintained
$275.00
+19.6%
05/08/2026
Louise Chen
Scotiabank
Buy
Maintained
$280.00
+21.7%
04/30/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$240.00
+4.3%
04/29/2026
Trung Huynh
RBC Capital
Buy
Maintained
$260.00
+13%
04/29/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$249.00
+8.3%
04/30/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$265.00
+15.2%
04/30/2026
Tim Anderson
Bank of America Securities
Buy
Upgraded
$234.00
+1.7%
04/30/2026
Asad Haider
Goldman Sachs
Hold
Reiterated
$244.00
+6.1%
04/29/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$262.00
+13.9%
04/20/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
04/01/2026
Nico Chen
DBS
Hold
Maintained
$230.00
-0%
02/25/2026
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.65 / $2.67
-0.77%miss
Revenue / Est. (USD)
15.00B / 14.72B
+1.93%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
15.42B
15.78B
16.62B
15.00B
Cost of goods sold
4.35B
4.46B
4.55B
4.22B
Cost of revenue
4.35B
4.46B
4.55B
4.22B
Research and development expenses
2.13B
2.29B
2.58B
2.47B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.18B
3.43B
3.82B
3.49B
Operating expense
5.29B
5.72B
6.40B
5.96B
Total operating expenses
9.64B
10.18B
10.95B
10.18B
Operating income
5.79B
5.60B
5.67B
4.82B
Other non operating income
91.00M
199.00M
120.00M
-21.00M
EBT including unusual items
1.55B
714.00M
2.67B
1.04B
EBT excluding unusual items
5.18B
5.11B
5.12B
4.17B
Income tax expense
613.00M
526.00M
853.00M
342.00M
Effective tax rate
39.45%
73.67%
31.97%
32.92%
Other operating expenses
-24.00M
-
-
-
Net income
938.00M
186.00M
1.82B
695.00M
Net profit margin
6.08%
1.18%
10.93%
4.63%
Earnings per share
2.97
1.86
2.71
2.65
Interest and investment income
62.00M
72.00M
59.00M
72.00M
Interest expense
-740.00M
-739.00M
-714.00M
-717.00M
Net interest expenses
-678.00M
-667.00M
-655.00M
-645.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.84B
7.66B
7.66B
6.76B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer